Peptide Drug Conjugation with Haptocorrin Binding Substrates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptide drugs face challenges such as instability in serum due to protease action, short half-life, and undesirable central nervous system (CNS) side effects, which limit their therapeutic effectiveness and lead to issues like nausea and weight loss.
Innovation Solution
Conjugating peptide drugs with haptocorrin-binding substrates, including vitamin B12 derivatives, to enhance pharmacokinetics and prevent CNS side effects by modifying their localization and reducing binding to transcobalamin II, thereby increasing half-life and minimizing side effects without causing vitamin B12 deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are administered to achieve therapeutic effects, then pharmacological activity is improved, but half-life is reduced due to rapid protease degradation
Solution Approach 1:
The patent uses haptocorrin as an intermediary binding protein that protects the peptide drug from protease degradation. The peptide is conjugated to a haptocorrin-binding substrate (such as vitamin B12 derivatives), creating a conjugate that binds to haptocorrin in the bloodstream. This haptocorrin-peptide conjugate system acts as a mediator that shields the peptide from enzymatic degradation while maintaining its pharmacological activity at the target receptor.
2Duration of action of moving object
If peptide drugs are conjugated to albumin binding proteins to improve half-life, then duration of action is improved, but drug efficacy is inhibited
Solution Approach 1:
The patent employs haptocorrin as a specialized intermediary that differs from conventional albumin binding approaches. Haptocorrin binds the peptide-conjugate in the bloodstream without interfering with the peptide's ability to interact with its target receptor. The haptocorrin-peptide complex serves as a protected reservoir that releases active peptide at the target site, maintaining both extended half-life and full drug efficacy.
3Reliability
If peptide drugs are administered to achieve therapeutic effects, then pharmacological activity is improved, but CNS side effects worsen due to unintended central nervous system access
Solution Approach 1:
The haptocorrin-binding conjugate system acts as a mediator that controls peptide distribution. Haptocorrin binds the peptide conjugate in the bloodstream, preventing unintended penetration into the central nervous system while allowing targeted delivery to peripheral receptors. This intermediary binding system selectively restricts access to specific brain regions, reducing CNS side effects while preserving therapeutic activity at the intended target.
4Duration of action of moving object
If B12 conjugates are used to improve pharmacokinetics, then half-life is extended, but vitamin B12 deficiency occurs due to binding by serum transcobalamin II
Solution Approach 1:
The patent applies local quality by designing the B12 conjugate with specific structural modifications that create distinct binding properties. The conjugated B12 molecule has altered local characteristics at the conjugation site that favor haptocorrin binding over transcobalamin II binding. This localized structural modification enables selective interaction with haptocorrin while avoiding competition with endogenous B12 transport, preventing B12 deficiency.
Solution Approach 2:
The patent changes key parameters of the B12 molecule through conjugation, including steric hindrance, electronic distribution, and binding affinity characteristics. These parameter changes modify the B12 conjugate's interaction profile with serum proteins, creating preferential binding to haptocorrin with dissociation constants in the nanomolar range while minimizing binding to transcobalamin II, thus avoiding B12 deficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugation approach significantly extends the half-life of peptide drugs, reduces CNS side effects like nausea and weight loss, and maintains therapeutic efficacy by altering their brain localization, ensuring effective glucoregulation without inducing vitamin B12 deficiency.
Implementation Method 1
The conjugation to certain B12 and/or related compounds allows the conjugate to become bound to unsaturated haptocorrin in the blood
Implementation Method 2
Such a route also would prevent, in all case save for actual vitamin B12s (e.g., cyanocobalamin; adenosylcobalamin, aquocobalamin), binding by serum transcobalamin II (TCII)
Data Source
AI summary
The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.